Palbociclib as an Antitumor Drug: A License to Kill
Neoplastic cells are characterized by uncontrolled cell divisions caused by cell cycle dysregulation. Key regulatory proteins governing the transition from the G1 to the S phase are the CDK4 and CDK6 kinases, which are controlled by D-type cyclins. The CDK4/6 kinases enable the use of these proteins...
Saved in:
| Main Authors: | Agnieszka Łupicka-Słowik, Federica Cossu, Marcin Sieńczyk |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/29/22/5334 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
by: Yaxun Guo, et al.
Published: (2024-11-01) -
Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors
by: John C. Panetta, et al.
Published: (2024-11-01) -
Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy
by: Rositsa Mihaylova, et al.
Published: (2024-12-01) -
Asymptotic analysis of mathematical model describing a new treatment of breast cancer using AZD9496 and palbociclib
by: Ophir Nave, et al.
Published: (2025-01-01) -
Palbociclib-induced Toxic Epidermal Necrolysis: A Case Report with Review of All Cases Secondary to Cyclin-dependent Kinase 4/6 Inhibitors
by: Aurore Devoldere, et al.
Published: (2025-01-01)